Perioperative Blood Management Strategies in Anemic Patients Undergoing Surgery: A Narrative Review - Cureus

IntroductionRisk stratification before definitive treatment is fundamental to prostate cancer management, guiding treatment intensity and patient counseling. The European Association of Urology (EAU) risk classification system, based on prostate-specific antigen (PSA), International Society of Urological Pathology (ISUP) grade group, and clinical stage, remains the cornerstone for treatment decision-making in patients undergoing radiotherapy (RT)1. Despite their clinical utility, outcome heterogeneity remains substantial. In a Swedish population-based cohort of patients treated with RT, the 15-year cumulative incidence of biochemical recurrence (BCR) ranged from 18% in EAU low-risk disease to 36% in EAU high-risk disease, indicating that currently used categories do not fully capture individual prognosis2. Improving pre-treatment prognostic stratification may therefore help identify clinically distinct subgroups within established categories.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.